5 terminated. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
| Phase 1 | 1 | Terminated 1 |
Follow Muscle Weakness: new trials by email Literature Review of Muscle Weakness trials Research Report on Muscle Weakness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy Bocidelpar, Placebo - Primary Mitochondrial Myopathy | Phase 2 | Terminated | Astellas Pharma Inc | 34 | 2021-05-24 | 2025-07-03 |
| Evaluating Muscle Weakness Improvement With Lorcaserin in ICU Lorcaserin, Placebo - Muscle Weakness, Sepsis | Phase 1 / Phase 2 | Terminated | Johns Hopkins University | 5 | 2015-12-01 | 2020-01-13 |
| Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease Cholecalciferol, Laboratory Biomarker Analysis, Multivitamin - Chronic Obstructive Pulmonary Disease, Muscle Weakness | Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2014-04-16 | 2017-02-15 |
| Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis BAF312, Placebo - Polymyositis, Dermatomyositis | Phase 2 | Terminated | Novartis Pharmaceuticals | 18 | 2010-06-15 | 2019-04-25 |
| Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) 3-4 Diaminopyridine - Muscle Weakness | Phase 2 | Terminated | Jeffrey A. Cohen, MD | 4 | 2004-02-01 | 2019-05-21 |
Deglutition Disorders (1) · Dermatomyositis (1) · Exanthema (1) · Fatigue (1) · Myositis (1) · Myositis, Inclusion Body (1) · Polymyositis (1) · Primary Dysautonomias (1) · Pulmonary Disease, Chronic Obstructive (1) · Reflex, Abnormal (1) · Sepsis (1) · Smoking Cessation (1)
Muscular Diseases (5) · Musculoskeletal Diseases (5) · Nervous System Diseases (5) · Neurologic Manifestations (5) · Neuromuscular Manifestations (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Autonomic Nervous System Diseases (1) · Behavior (1) · Chronic Disease (1) · Connective Tissue Diseases (1) · Digestive System Diseases (1) · Disease Attributes (1) · Esophageal Diseases (1)
Cholecalciferol (1) · Geritol (1) · lorcaserin (1) · siponimod (1)
Astellas Pharma Inc (1) · Jeffrey A. Cohen, MD (1) · Johns Hopkins University (1) · Novartis Pharmaceuticals (1) · Roswell Park Cancer Institute (1)
United States (5) · Czechia (1) · Hungary (1) · Sweden (1) · United Kingdom (1)
Dale M Needham, MD, PhD (1) · Jeffrey A. Cohen, MD (1) · Martin Mahoney (1)
2008 (1), P30CA016056 (1), P50CA090440 (1), UL1TR001079 (1)